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Vaccine Nationalism 
By David Hearne, researcher, Centre for Brexit Studies 
We are currently in the midst of a rather ugly spat over access to 
vaccines for the novel coronavirus. Unsurprisingly, this has been 
blown up and escalated into something of a war of words. 
In the UK, this has been exaggerated and distorted by a largely 
Eurosceptic press into a Brexit-related issue. However, whilst Brexit is 
a tangential factor, it is not central. Similarly, misinformation abounds 
online, propagated largely either by those with an agenda or others 
who are spoiling for a fight. 
Firstly, let us consider the background: pre-pandemic, vaccines were 
something of a poor relation compared to many therapeutics. In 
wealthy countries, vaccines were routine medicines needed in modest 
quantities. Most of us received vaccines against several deadly 
diseases during early childhood. Very occasionally, boosters or 
specific vaccines are desirable for certain purposes (e.g. for certain 
international travel). In fact, proof of vaccination against Yellow Fever 
is a prerequisite to enter certain countries. 
The major exception to this is against flu, where many of us receive 
vaccination on an annual basis. Again, however, the processes 
around this are well-established, demand is stable and the technology 
is mature. As a result, domestic promotion of vaccine manufacture 
(on-shoring) has not been a priority for most wealthy countries over 
the years. Similarly, the amount of money committed to vaccine 
research pre-2020 stands in marked contrast to the huge money 
spent on research into therapies to treat cancer. 
The fact that so much global vaccine manufacture is concentrated in 
India tells a great deal about the economics of it (although this is not 
to understate either the business acumen or global importance of 
work done by Indian companies, particularly the Serum Institute of 
India). This is the background against which the remarkable 
achievements of scientists and engineers in terms of developing and 
manufacturing vaccines multiple vaccines against a novel illness must 
be seen. 
As such, supply for new vaccines has had to be developed in record 
time. Nor are these trivial things to scale up in a short period. In other 
words, there are good technical reasons why supply is limited 
(otherwise we’d all be vaccinated by now!). 
However, at the time of writing, most EU nations have delivered 
substantially fewer vaccinations per capita than some other wealthy 
countries, including Israel, the US and the UK. This is, 
understandably, causing some consternation and it’s worth 
considering the reasons why. 
The EU Commission has been engaged in a very public dispute with 
AstraZeneca over vaccine supply. Let us be honest: whatever the 
rights and wrongs of the case (and I have much sympathy with EU 
citizens and others who are desperately awaiting a vaccine) this is a 
distraction from the wider issue. 
Specifically, the UK placed firm orders for 100m doses of the vaccine 
manufactured by AstraZeneca. The EU placed firm orders for 300m 
doses. Due to the complexities of manufacture, AstraZeneca has 
been able to deliver fewer doses than promised. Nobody is 
suggesting that this is anything other than an unfortunate result of 
manufacturing difficulties. 
There is some confusion over the exact amount set to be delivered to 
the EU by the end of the first quarter. However, we know that 17m 
AstraZeneca doses have been distributed to EU member states as of 
25th March (1). We don’t have equivalent figures for the UK, but some 
guesswork will suffice. 
The UK has allegedly received 13m doses of the vaccine 
manufactured by Pfizer and has administered around 31m doses in 
total (2) implying that the UK has received around 18m doses. The 
EU’s suggestion is that AstraZeneca should have shared the 
shortcomings in proportion to the contracts, which seems a 
reasonable approach. Had that happened, the EU would have 
received an extra 9m doses and the UK 9m fewer. 
The extra 9m doses would be sufficient to give an extra 2 doses per 
100 people – moving the EU from 14 to 16 doses administered per 
100 people. Hardly earth-shattering. For the UK, the figure would fall 
from 45.9 to 32.3. A more significant setback but it would still leave 
the UK having administered double the rate of the EU. 
In fact, the situation is even more bizarre, because there are some 7m 
doses of the AstraZeneca-manufactured vaccine waiting to be 
administered in the EU – 40% of the total deliveries. Given this 
bottleneck it is far from clear that an extra 9m doses would help. In 
other words, the disagreement with AstraZeneca can only explain a 
small part of the EU’s issues with regard to vaccines. Several factors 
appear to have contributed to the UK’s faster rollout relative to its EU 
neighbours. 
Firstly, the Medicines and Healthcare products Regulatory Authority 
(MHRA) was very quick to grant approval to vaccines, allowing the UK 
to get its vaccination campaign underway early. This was not 
(explicitly) due to Brexit: emergency use authorisation was granted 
when the UK was still in the Single Market. However, EU members 
waited for the EMA to authorise (using a slower conditional marketing 
authorisation). To reiterate, this was a decision on the part of medical 
regulators and not the government. The MHRA appears to have 
consistently taken a pragmatic approach. The benefits of speedy 
approval clearly outweighed the (minimal) risks, particularly given the 
wave of illness engulfing the UK at the time. 
Similarly, extending the gap between doses was a calculated risk – 
the evidence was strongly suggestive of the first dose giving 
substantial initial protection and, in the case of the AstraZeneca 
vaccine there were hints (later confirmed) that a 12 week gap might 
prove more effective than a 4 week one. 
In a normal situation, extreme caution with vaccines is warranted: you 
are giving medicines to otherwise healthy individuals. It makes sense 
to await voluminous data and suspend inoculations at the merest hint 
of any issues – no matter how unlikely. The cost of doing so is 
typically low. However, we are not in a normal situation. Thousands 
are dying daily. 
We’ve seen this again with national medical regulators, particularly 
with respect to the AstraZeneca vaccine. The costs of pausing 
vaccinations, awaiting even more data (whether on the elderly, blood 
clots etc.) in order to triple check things are astronomical. Worse, 
doing so appears to be undermining trust in a vaccine that is both safe 
and effective. 
The other major factor slowing the EU’s rollout of vaccinations is 
procurement. Specifically, the UK waived manufacturer liability for 
vaccines, instantly making it more attractive. The EU also typically 
came to agreements later, paid a lower price and invested 
significantly less (on a per capita basis) than either the UK or US. 
I have no doubt that the Commission were diligent in ensuring that all 
correct procedures were followed and that the EU got value for 
money. Unfortunately, on this occasion, that approach did not work. 
Addendum 
So how concerned should Britons be over threats to block vaccines? 
The UK has already given a first dose to those most at risk and has 
enough manufacturing capacity to give second doses of the 
AstraZeneca vaccine. The big challenge relates to the Pfizer-
manufactured vaccine – millions are currently awaiting a second dose. 
Ultimately, I think we can be fairly sanguine. The UK can, at this 
juncture, afford to be much more generous with its supplies of the 
AstraZeneca-manufactured vaccine. For reasons of ethics and 
political expediency, it should do so. I will live without my vaccine for a 
few weeks longer! 
1. https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-
19/vaccine-tracker.html#distribution-tab 
2. https://coronavirus.data.gov.uk/details/vaccinations 
 
